Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Vietnam has been experiencing steady growth in recent years.
Customer preferences: Vietnamese customers tend to prefer generic drugs over branded ones due to their affordability. This preference has led to an increase in the production and consumption of generic immunosuppressants in the country.
Trends in the market: The market for immunosuppressants in Vietnam is mainly driven by the rising incidence of autoimmune diseases and organ transplantation. The country is witnessing an increase in the number of patients suffering from autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis. Additionally, the demand for immunosuppressants is also increasing due to the rise in organ transplantation surgeries.
Local special circumstances: Vietnam has a universal healthcare system that provides free or low-cost healthcare services to its citizens. This has led to an increase in the demand for immunosuppressants, as more people are able to access healthcare services. Moreover, the government has been making efforts to improve the quality of healthcare services in the country, which has also contributed to the growth of the immunosuppressants market.
Underlying macroeconomic factors: Vietnam is experiencing rapid economic growth, which has led to an increase in disposable incomes and an improvement in the standard of living. This has resulted in an increase in healthcare spending, including spending on immunosuppressants. Additionally, the country has a large and growing elderly population, which is more susceptible to autoimmune diseases, thereby contributing to the growth of the immunosuppressants market.In conclusion, the immunosuppressants market in Vietnam is growing steadily due to the rising incidence of autoimmune diseases and organ transplantation, customer preference for generic drugs, and the country's universal healthcare system. The underlying macroeconomic factors such as rapid economic growth, an increase in disposable incomes, and an aging population are also contributing to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
